RESUMEN
Reformulation with addition of antioxidants is one potential mitigation strategy to prevent or reduce nitrosamine drug substance-related impurities (NDSRIs) in drug products. To explore whether there could be other approaches to demonstrate bioequivalence for a reformulated oral product, which typically needs in vivo bioequivalence studies to support the changes after approval, the effects of antioxidant on the in vitro permeability of BCS III model drug substances were investigated to see whether there could be any potential impact on drug absorption. Six antioxidants were screened and four (ascorbic acid, cysteine, α-tocopherol and propyl gallate) were selected based on their nitrosamine inhibition efficiencies. The study demonstrated that these four antioxidants, at the tested amounts, did not have observable impact on the in vitro permeability of the BCS III model drug substances across Caco-2 cell monolayers in the In Vitro Dissolution Absorption System (IDAS). An in vitro permeability study could be considered as part of one potential bioequivalence bridging approach for reformulated low-risk immediate release solid oral products and oral suspension products. Other factors such as the influence of antioxidants on intestinal transporter activities should be considered where appropriate.
Asunto(s)
Antioxidantes , Permeabilidad , Humanos , Células CACO-2 , Antioxidantes/farmacología , Antioxidantes/farmacocinética , Permeabilidad/efectos de los fármacos , Absorción Intestinal/efectos de los fármacos , Equivalencia Terapéutica , Ácido Ascórbico/farmacología , Preparaciones Farmacéuticas/metabolismo , Preparaciones Farmacéuticas/química , alfa-Tocoferol/farmacología , Solubilidad , Cisteína/química , Administración OralRESUMEN
A network of regulatory innovations brings a holistic approach to improving the submission, assessment, and lifecycle management of pharmaceutical quality information in the U.S. This dedicated effort in the FDA's Center for Drug Evaluation and Research (CDER) aims to enhance the quality assessment of submissions for new drugs, generic drugs, and biological products including biosimilars. These regulatory innovations include developing or contributing: (i) the Knowledge-Aided Assessment and Structured Application (KASA), (ii) a new common technical document for quality (ICH M4Q(R2)), (iii) structured data on Pharmaceutical Quality/Chemistry, Manufacturing and Controls (PQ/CMC), (iv) Integrated Quality Assessment (IQA), (v) the Quality Surveillance Dashboard (QSD), and (vi) the Established Conditions tool from the ICH Q12 guideline. The innovations collectively drive CDER toward a more coordinated, effective, and efficient quality assessment. Improvements are made possible by structured regulatory submissions, a systems approach to quality risk management, and data-driven decisions based on science, risk, and effective knowledge management. The intended result is better availability of quality medicines for U.S. patients.
RESUMEN
Continuous manufacturing (CM) sends materials directly and continuously to the next step of a process, eliminating hold times and reducing processing times. The potential benefits of CM include improved product quality, reduced waste, lower costs, and increased manufacturing flexibility and agility. Some pharmaceutical manufacturers have been hesitant to adopt CM owing to perceived regulatory risks such as increased time to regulatory approval and market entry, more difficulty submitting postapproval changes, and higher inspectional scrutiny. An FDA self-audit of regulatory submissions in the U.S. examined the outcomes, at approval and during the product lifecycle, of continuous manufacturing applications as compared to traditional batch applications. There were no substantial regulatory barriers identified for CM applications related to manufacturing process changes or pre-approval inspections. CM applicants had relatively shorter times to approval and market as compared to similar batch applications, based on the mean or median times to approval (8 or 3 months faster) and marketing (12 or 4 months faster) from submission, translating to an estimated $171-537 M in early revenue benefit.
Asunto(s)
Tecnología Farmacéutica , Preparaciones FarmacéuticasAsunto(s)
Química Farmacéutica/normas , Congresos como Asunto/normas , Industria Farmacéutica/normas , Control de Calidad , United States Food and Drug Administration/normas , Química Farmacéutica/tendencias , Congresos como Asunto/tendencias , Industria Farmacéutica/tendencias , Humanos , Estados Unidos , United States Food and Drug Administration/tendenciasRESUMEN
On September 16 and 17, 2014, the Food and Drug Administration (FDA) and Product Quality Research Institute (PQRI) inaugurated their Conference on Evolving Product Quality. The Conference is conceived as an annual forum in which scientists from regulatory agencies, industry, and academia may exchange viewpoints and work together to advance pharmaceutical quality. This Conference Summary Report highlights key topics of this conference, including (1) risk-based approaches to pharmaceutical development, manufacturing, regulatory assessment, and post-approval changes; (2) FDA-proposed quality metrics for products, facilities, and quality management systems; (3) performance-based quality assessment and clinically relevant specifications; (4) recent developments and implementation of continuous manufacturing processes, question-based review, and European Medicines Agency (EMA)-FDA pilot for Quality-by-Design (QbD) applications; and (5) breakthrough therapies, biosimilars, and international harmonization, focusing on ICH M7 and Q3D guidelines. The second FDA/PQRI conference on advancing product quality is planned for October 5-7, 2015.
Asunto(s)
Diseño de Fármacos , Preparaciones Farmacéuticas/normas , Aprobación de Drogas , Humanos , Control de Calidad , Estados Unidos , United States Food and Drug AdministrationAsunto(s)
Academias e Institutos/organización & administración , Investigación Biomédica/organización & administración , Cardiología/organización & administración , United States Food and Drug Administration/organización & administración , Academias e Institutos/normas , Investigación Biomédica/normas , Cardiología/instrumentación , Cardiología/normas , Consenso , Conducta Cooperativa , Diseño de Equipo , Seguridad de Equipos , Humanos , Relaciones Interinstitucionales , Objetivos Organizacionales , Terminología como Asunto , Estados Unidos , United States Food and Drug Administration/normasAsunto(s)
Angioplastia Coronaria con Balón/instrumentación , Angioplastia Coronaria con Balón/legislación & jurisprudencia , Enfermedad de la Arteria Coronaria/terapia , Aprobación de Recursos/legislación & jurisprudencia , Stents Liberadores de Fármacos , Regulación Gubernamental , Política de Salud , United States Food and Drug Administration/legislación & jurisprudencia , Angioplastia Coronaria con Balón/efectos adversos , Ensayos Clínicos como Asunto , Determinación de Punto Final , Medicina Basada en la Evidencia , Adhesión a Directriz , Humanos , Inhibidores de Agregación Plaquetaria/uso terapéutico , Guías de Práctica Clínica como Asunto , Medición de Riesgo , Trombosis/etiología , Trombosis/prevención & control , Resultado del Tratamiento , Estados UnidosAsunto(s)
Aprobación de Recursos/normas , Sistemas de Liberación de Medicamentos/normas , Stents/efectos adversos , Sistemas de Liberación de Medicamentos/efectos adversos , Sistemas de Liberación de Medicamentos/métodos , Humanos , Guías de Práctica Clínica como Asunto , Stents/normas , Trombosis/etiología , Estados Unidos , United States Food and Drug AdministrationRESUMEN
BACKGROUND: Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation. METHODS AND RESULTS: The Academic Research Consortium is an informal collaboration between academic research organizations in the United States and Europe. Two meetings, in Washington, DC, in January 2006 and in Dublin, Ireland, in June 2006, sponsored by the Academic Research Consortium and including representatives of the US Food and Drug Administration and all device manufacturers who were working with the Food and Drug Administration on drug-eluting stent clinical trial programs, were focused on consensus end point definitions for drug-eluting stent evaluations. The effort was pursued with the objective to establish consistency among end point definitions and provide consensus recommendations. On the basis of considerations from historical legacy to key pathophysiological mechanisms and relevance to clinical interpretability, criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed. The broadly based consensus end point definitions in this document may be usefully applied or recognized for regulatory and clinical trial purposes. CONCLUSION: Although consensus criteria will inevitably include certain arbitrary features, consensus criteria for clinical end points provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
Asunto(s)
Ensayos Clínicos como Asunto/métodos , Ensayos Clínicos como Asunto/normas , Enfermedad Coronaria/mortalidad , Enfermedad Coronaria/terapia , Stents , Reestenosis Coronaria/mortalidad , Reestenosis Coronaria/prevención & control , Sistemas de Liberación de Medicamentos , Humanos , Trombosis/mortalidad , Trombosis/prevención & controlAsunto(s)
Enfermedad Coronaria/terapia , Trombosis Coronaria/etiología , Aprobación de Recursos , Stents/efectos adversos , United States Food and Drug Administration , Comités Consultivos , Angioplastia Coronaria con Balón , Sistemas de Liberación de Medicamentos , Humanos , Infarto del Miocardio/etiología , Diseño de Prótesis , Falla de Prótesis , Riesgo , Estados UnidosRESUMEN
Coronary drug-eluting stents (DES) are a breakthrough technology that has changed the standard of care for many patients undergoing percutaneous intervention for coronary artery disease. Initial trials of two DES demonstrated significant clinical benefit with respect to the need for reintervention when compared with bare metal stents. However, more recent studies of DES involve in-patients with more complex disease, such as bifurcation lesions, chronic total occlusions and multiple-vessel disease. Additionally, DES are now being evaluated in patients previously only considered for surgical intervention. Assessment of DES in these complicated patient populations can lead to challenges in trial design, but the US FDA is willing to consider alternative clinical trial designs and statistical analysis plans. Other complex issues associated with DES include duration of clinical trials to determine safety, and the appropriate dose and duration of concomitant antiplatelet therapy. Finally, the FDA acknowledges that DES are complex products to produce and we believe that through interaction with the FDA during development, difficulties with test methodologies, animal studies and clinical trial designs can be addressed. The future of DES likely involves new stent and carrier materials, including biodegradable materials and new drugs and biologicals. The FDA anticipates continued collaboration with physicians, manufacturers, academic institutions and professional societies.
Asunto(s)
Prótesis Vascular/normas , Aprobación de Recursos/legislación & jurisprudencia , Fibrinolíticos/administración & dosificación , Oclusión de Injerto Vascular/prevención & control , Política Pública , Stents/normas , United States Food and Drug Administration , Prótesis Vascular/efectos adversos , Reestenosis Coronaria/etiología , Reestenosis Coronaria/prevención & control , Implantes de Medicamentos/administración & dosificación , Oclusión de Injerto Vascular/etiología , Humanos , Stents/efectos adversos , Estados UnidosAsunto(s)
Ensayos Clínicos como Asunto/métodos , Sistemas de Liberación de Medicamentos/métodos , Vigilancia de Productos Comercializados/métodos , Stents , Animales , Reestenosis Coronaria/diagnóstico , Reestenosis Coronaria/etiología , Estenosis Coronaria/terapia , Diseño de Equipo , Humanos , Dosis Máxima Tolerada , Modelos Animales , Farmacocinética , Recurrencia , Proyectos de Investigación , Stents/efectos adversosRESUMEN
Data from the U.S. Food and Drug Administration, the American Academy of Ophthalmology's National Eyecare Outcomes Network, and Storm Eye Institute databases were analyzed for short- and long-term safety and efficacy outcomes of intraocular lens (IOL) implantation in adults younger than 60 years and 60 years and older. Statistical analyses for significance were performed where appropriate. A comprehensive literature review was conducted to identify safety and efficacy outcomes and their relationship to patient age at the time of implantation. Analyses established that the performance of IOLs in adults younger than 60 years was comparable to that in adults older than 60 years and supported the use of IOLs in the younger adult population.